Effect of Two Intensive Statin Regimens on Progression of Coronary Disease

Stephen J. Nicholls(Australian Centre for Heart Health), Steven E. Nissen(Cleveland Clinic), Christie M. Ballantyne(Baylor College of Medicine), M. John Chapman(Sorbonne Université), Philip J. Barter(The Heart Research Institute), Marilyn Borgman(Cleveland Clinic), Kathy Wolski(Cleveland Clinic), Kiyoko Uno(Cleveland Clinic), Joel S. Raichlen(AstraZeneca (United Kingdom)), Raimund M. Erbel(West German Heart and Vascular Center Essen), Peter Libby(Harvard University)
New England Journal of Medicine
November 16, 2011
10.1056/nejmoa1110874
Cited by 891

Related Papers

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
|European Heart Journal|2017|3.8k
Inflammation in Atherosclerosis
|Arteriosclerosis Thrombosis and Vascular Biology|2012|3.7k
ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
|European Heart Journal|2011|3.5k